[Efficacy and safety of belimumab treatment in childhood-onset systemic lupus erythematosus].

Kang, M; Zhu, J; Xu, Y J; Li, S N; Lai, J M

Kang, M; Zhu, J; Xu, Y J; Li, S N; Lai, J M.

Afiliación

Kang M; Department of Rheumatology and Immunology, Children's Hospital Affiliated to Capital Institute of Pediatrics, Beijing 100020, China.
Zhu J; Department of Rheumatology and Immunology, Children's Hospital Affiliated to Capital Institute of Pediatrics, Beijing 100020, China.
Xu YJ; Department of Rheumatology and Immunology, Children's Hospital Affiliated to Capital Institute of Pediatrics, Beijing 100020, China.
Li SN; Department of Rheumatology and Immunology, Children's Hospital Affiliated to Capital Institute of Pediatrics, Beijing 100020, China.
Lai JM; Department of Rheumatology and Immunology, Children's Hospital Affiliated to Capital Institute of Pediatrics, Beijing 100020, China.

Zhonghua Yi Xue Za Zhi ; 102(48): 3881-3885, 2022 Dec 27.

Article en Zh | MEDLINE | ID: mdl-36540927

Asunto(s)

Anticuerpos Monoclonales Humanizados; Lupus Eritematoso Sistémico; Humanos; Masculino; Niño; Adolescente; Femenino; Prednisona/uso terapéutico; Resultado del Tratamiento; Anticuerpos Monoclonales Humanizados/uso terapéutico; Lupus Eritematoso Sistémico/tratamiento farmacológico; Inmunosupresores/uso terapéutico

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Anticuerpos Monoclonales Humanizados / Lupus Eritematoso Sistémico Idioma: Zh Revista: Zhonghua Yi Xue Za Zhi Año: 2022 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google